SCYNEXIS, Inc. (SCYX)
NASDAQ: SCYX · Real-Time Price · USD
0.7444
-0.0264 (-3.43%)
At close: May 15, 2026, 4:00 PM EDT
0.7400
-0.0044 (-0.59%)
After-hours: May 15, 2026, 4:10 PM EDT
SCYNEXIS Earnings Call Transcripts
Fiscal Year 2026
-
Acquisition of SCY-770 marks a strategic shift to rare renal diseases, targeting ADPKD with a promising, selective AMPK activator. The deal provides global rights, strong IP, and financial runway to 2029, positioning the company for leadership in a large, underserved market.
Fiscal Year 2024
-
Key updates included progress on antifungal partnerships, especially with GSK, and advancement of next-generation compound SCY-247 toward first-in-human studies by year-end. The company maintains a strong financial position and is recognized as a leader in antifungal innovation.